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INTRODUCTION
Differentiation of activated B cells during the initial stages of 
T cell–dependent antibody responses proceeds simultaneously 
along pathways leading to early (extrafollicular) plasmablasts 
(PBs), germinal center (GC) B cells, and GC-independent, 
early memory B cells. These pathways differ in their spatio-
temporal emergence, the longevity of their end products, 
their affinity for antigens, and their functional capacity (Tay-
lor et al., 2012) and are considered important for establishing 
robust and diverse antibody responses. Adoption of these fates 
is controlled in part by B cell–trafficking receptors, which 
are dynamically regulated after antigen engagement to en-
able B cell access to antigens, interactions with T cells, and 
positioning in distinct lymphoid niches that foster the for-
mation of immediate or long-lasting, antigen-specific anti-
body responses (Pereira et al., 2010). How antigen-activated B 
cells regulate their response to the several chemoattractants to 
which they may be simultaneously or sequentially exposed is 
uncertain. It is, however, potentially crucial as a mechanism in 
determining stoichiometry in the distribution of B cells along 
the differentiation pathways that generate the effector B cells 
of the immune response.
A key event in the initiation of T cell–dependent hu-
moral immune responses is the CCR7-directed migration 
of antigen-engaged B cells toward, and subsequent EBI2/
CXCR5/CCR7-dependent distribution along, the bor-
der between the T cell and B cell zones (Reif et al., 2002; 
Okada et al., 2005; Chan et al., 2009; Gatto et al., 2009, 2011; 
Pereira et al., 2009; Hannedouche et al., 2011; Kelly et al., 
2011). Cognate T and B cell interactions at this interface drive 
EBI2-mediated relocalization to the interfollicular and outer 
follicular regions in which activated B cells initially proliferate 
(Chan et al., 2009; Gatto et al., 2009; Kelly et al., 2011; Ker-
foot et al., 2011). Proliferating B cells subsequently trifurcate 
their differentiation trajectories, adopting a chemoattractant 
receptor profile that drives their positioning to lymphoid mi-
croenvironments that promote their effector function. Early 
PB differentiation is coupled with the induction of CXCR4 
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and down-regulation of CXCR5 and CCR7, which repo-
sitions these cells in extrafollicular niches and the splenic 
red pulp (Hargreaves et al., 2001). These PBs are short lived 
and elicit the first line of antigen-specific antibody defense 
(Smith et al., 1996). GC-committed B cells down-regulate 
EBI2 (Gatto et al., 2009; Pereira et al., 2009) but maintain 
CXCR4 and CXCR5 expression (Allen et al., 2004), draw-
ing them into the follicular dendritic cell–rich follicle center 
where GCs form. Another subset of B cells ultimately adopts 
a trafficking receptor profile that allows its continuous recir-
culation through the blood and secondary lymphoid organ 
follicles as early memory B cells, which retain their germ-
line-encoded antibody. Whether the spatiotemporal control 
of B cell chemoattractant responsiveness, which is a crucial 
component of activated B cell differentiation, is stochastic or 
is intrinsic to the identified receptors and ligands and whether 
other receptors are involved remain unknown.
Recent studies have shown that a subfamily of atypi-
cal chemokine receptors regulates cellular migration (Nibbs 
and Graham, 2013). These receptors are uncoupled from the 
classic chemokine receptor-signal transduction machinery, 
do not induce cell migration, are mainly expressed outside 
the hematopoietic compartment, and mediate chemokine re-
moval or redistribution in vivo (Nibbs and Graham, 2013). 
Atypical chemokine receptor 4 (ACKR4) binds CCR7 li-
gands CCL19 and CCL21 and the CCR9 ligand CCL25 and, 
thus, regulates their bioavailability in vivo without initiating 
cellular migration (Gosling et al., 2000; Comerford et al., 
2006, 2010; Heinzel et al., 2007; Bunting et al., 2013; Ulvmar 
et al., 2014; Lucas et al., 2015; Bryce et al., 2016). However, 
despite the important role of CCR7 in the development of T 
cell–dependent antibody responses, the function of ACKR4 
in this context is unknown. We now report an important, 
B cell–intrinsic role for ACKR4 in regulating B cell differ-
entiation during the initial stages of the T cell–dependent 
humoral immune response.
RESULTS AND DISCUSSION
Although a previous study (Heinzel et al., 2007) concluded 
that ACKR4 is expressed exclusively by cells of nonhemato-
poietic origin in unimmunized mice, we detected ACKR4 
transcripts and protein expression by GC B cells (Fig. 1, A 
and B). To investigate the possible functions for hematopoi-
etic ACKR4 in T cell–dependent humoral immunity, we used 
bone marrow (BM) chimerism to generate mice in which 
ACKR4 deficiency was restricted to the hematopoietic com-
partment (H-Ackr4−/−). We immunized these H-Ackr4−/− 
mice with sheep red blood cells (SRBCs) and observed an 
increased frequency of GC B cells at all time points assessed 
after immunization but most prominently on day 5 relative to 
hematopoietic WT (H-WT) mice (Fig. 1 C). The number of 
T follicular helper (TFH) cells, mediators of GC B cell selec-
tion and proliferation, and T follicular regulatory (TFR) cells, 
implicated in regulating the magnitude of the GC reaction, 
were also increased in immunized H-Ackr4−/− mice relative 
to controls (Fig. S1 A). The formation of early PBs, despite a 
lack of detectable ACKR4 expression, in H-Ackr4−/− mice 
was also enhanced on day 5 of the response (Fig. 1 D). These 
data reveal a negative regulatory role for ACKR4 expression 
in the hematopoietic compartment on early PB and GC B cell 
development. To determine whether this effect was intrinsic 
to B cell expression of ACKR4, we reconstituted lethally irra-
diated mice with a 4:1 mixture of BM recovered from B cell–
deficient (μMT) mice that lack endogenous B cells (Kitamura 
et al., 1991) and either WT (B-WT) or Ackr4−/− (B-Ackr4−/−) 
mice. Immunizing B-Ackr4−/− mice with SRBC reproduced 
the increased numbers of splenic GC B cells, TFH cells, and 
early PBs seen in immunized H-Ackr4−/− mice (Fig. 1, E and 
F; and Fig. S1 B). Collectively, these data reveal a B cell–in-
trinsic regulatory role for ACKR4 in the early stages of the B 
cell response to a T cell–dependent antigen.
ACKR4 expression by GC B cells (Fig. 1, A and B), and 
their disproportionate expansion in immunized H-Ackr4−/− 
and B-Ackr4−/− mice (Fig. 1, C and F), prompted us to inves-
tigate whether ACKR4 functioned in GC biology. ACKR4 
internalizes and degrades CCR7 ligands without initiating 
cellular migration (Gosling et al., 2000; Townson and Nibbs, 
2002; Comerford et al., 2006; Heinzel et al., 2007). However, 
CCL21 staining appeared to be normal around established 
Ackr4-deficient GCs in histologic sections of mesenteric LNs 
from H-Ackr4−/− mice (Fig. 2 A). This suggests that GC B 
cell expression of ACKR4 does not determine the abundance 
or localization of CCL21 outside GCs. GC B cells cycle be-
tween light zones (LZs) and dark zones (DZs) of the GCs, 
reflecting the iterative process of affinity-based selection, pro-
liferation, and Ig somatic hypermutation that drives antibody 
affinity maturation (Victora and Nussenzweig, 2012). Flow cy-
tometric assessment of DZ (CXCR4hiCD86lo) and LZ (CX-
CR4loCD86hi) GC B cell phenotypes (Victora et al., 2010; 
Bannard et al., 2013) revealed no differences between H-WT 
and H-Ackr4−/− GCs (Fig. 2 B). Further, GC B cell prolif-
eration and apoptosis were equivalent between H-WT and 
H-Ackr4−/− mice as measured by BrdU incorporation, DNA 
content, and Annexin V analyses (Fig.  2, C and D). Assess-
ment of affinity maturation using Ig heavy chain–variable (V) 
region sequencing of individual (4-hydroxy-3-nitrophenyl)
acetyl (NP)–specific IgG1+ GC B cells revealed that over-
all somatic mutations and the affinity-enhancing W to L re-
placement at position VH33 accumulated at similar rates in 
Ackr4-deficient and -sufficient GCs (Fig. 2 E). Serum anti-
body titers of NP-specific IgG were enhanced in H-Ackr4−/− 
mice at day 21 after immunization; however, the ratio of 
NP5- (high affinity) to NP32- (global affinity) reactive IgG was 
equivalent between H-WT and H-Ackr4−/− mice (Fig. 2 F). 
In addition, we addressed whether ACKR4 influenced GC 
B cell–affinity maturation in a cell-intrinsic manner. To do 
this, we crossed Ackr4−/− mice to SWHEL Ig transgenic mice 
(SWHEL.Ackr4−/−) and measured GC B cell–affinity matu-
ration in competition with WT SWHEL B cells after trans-
fer. SWHEL B cells express a B cell receptor (BCR) derived 
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from the hen egg lysozyme (HEL)–specific HyHEL10 mAb 
(Brink et al., 2015). Immunization with the reduced-affinity 
HEL mutant HEL3X (acid dissociation constant [Ka] = 1 × 
107 M−1) elicits a SWHEL GC B cell response characterized by 
a Y53D substitution in the Ig heavy chain V region, which in-
creases HyHEL10 affinity to HEL3X by >100-fold (Paus et al., 
2006; Chan et al., 2012; Brink et al., 2015). The additionally 
reduced affinity HEL mutant HEL4X (Ka = 2.3 × 105 M−1) 
does not bind the SWHEL BCR in a physiologically relevant 
manner but can bind the Y53D mutant form of HyHEL10 
selected during the SWHEL GC response to HEL3X (Chan et 
al., 2012), thereby providing a metric for affinity maturation 
in the anti–HEL3X response. WT (CD45.1/2) and Ackr4−/− 
(CD45.2) SWHEL B cells were cotransferred into CD45.1 
congenic recipient mice and immunized with HEL3X-SRBC 
(Fig.  2  G). On day 9, DZ/LZ phenotypes (Fig.  2  H) and 
the frequency of HEL4X-binding GC B cells (Fig. 2 I) were 
equivalent between WT and Ackr4−/− SWHEL GC B cells, 
indicating that, in this system, the absence of ACKR4 on GC 
B cells does not compromise the processes of affinity-based 
selection or establishment of DZ and LZ phenotypes in the 
presence of competing ACKR4-sufficient GC B cells. Col-
Figure 1. B cell ACKR4 limits early PB and GC B cell responses. (A) Quantitative PCR analysis of Ackr4 transcript abundance in sorted Fo B cells 
(B220+IgD+Fas−GL7−), GC B cells (B220+IgD−Fas+GL7+), and early PB (B220lo/-CD138+) relative to the housekeeping gene Rplp0 (means ± SD). (B) Represen-
tative histogram of CCL19–Fc staining on GC B cells from Ackr4−/−.Ccr7−/− (cannot bind CCL19–Fc), Ackr4−/− (CCR7 staining), Ccr7−/− (ACKR4 staining), and 
WT (ACKR4/CCR7 staining) mice. Graphs plot geometric mean fluorescence intensity (GMFI) of CCL19-Fc staining on Fo B cells, GC B cells, and early PBs, 
gated as in A (n = 5 mice/genotype; means ± SEM). (C and D) H-Ackr4−/− and H-WT mice were generated by reconstituting lethally irradiated B6.Ly5.1 mice 
with BM from Ackr4−/− or WT mice, respectively. Representative plots of splenic GC B cell (C) and early PB (D) populations day 5 after SRBC immunization. 
Numbers in plots present the means ± SEM frequency of GC B cells per total B220+ cells (C) or early PBs per spleen (D). Graphs present the total number 
of GC B cells (C) and early PB (D) per spleen on the days indicated after immunization. n = 3 (day 0); n = 8 (day 5); n = 8 (day 8); and n = 5 (day 14) mice/
genotype; means ± SEM). (E and F) B cell–Ackr4−/− (B-Ackr4−/−) and B-WT mice were generated by reconstituting lethally irradiated B6.Ly5.1 mice with a 
mixture of BM from μMT (80%) and Ackr4−/− mice or WT mice (20%), respectively. Graphs plot the total number of GC B cells (E) and early PB (F) per spleen 
on the days indicated after SRBC. (A–F) n = 7 (day 5) and n = 8 (day 8) mice/genotype; means ± SEM. Data are representative of two independent experi-
ments. *, P < 0.05; **, P < 0.01; ***, P < 0.001. (B) One-way analysis of variance with the Bonferroni multiple-comparisons test. (C–F) Two-tailed, unpaired 
Student’s t test or two-tailed, nonparametric Mann-Whitney test, as appropriate.
ACKR4 shapes activated B cell fate | Kara et al.804
lectively, these data show GC B cell proliferation, apoptosis, 
DZ/LZ phenotype ratio, somatic hypermutation, and affin-
ity maturation to be unaltered in Ackr4-deficient GCs and 
suggest, instead, that B cell expression of ACKR4 negatively 
regulates, specifically, the pre-GC stages of development 
of the B cell response.
Our findings in H-Ackr4−/− and B-Ackr4−/− mice in-
dicated that ACKR4 negatively regulates both early PB and 
GC B cell responses (Fig. 1, C–G). Recent evidence has indi-
cated that a single B cell clone can enter all three possible dif-
ferentiation fates, and that this positively correlates with the 
magnitude of their early proliferation and resistance to apop-
tosis (Taylor et al., 2015). Based on these observations and 
our data, we hypothesized that ACKR4 functions in undif-
ferentiated, activated B cells to negatively regulate both early 
PB and GC B cell responses. This hypothesis predicts that 
Ackr4-deficient B cells will preferentially enter early PB and 
GC B compartments in an environment in which Ackr4−/− 
and WT B cells are in competition. To test this, we studied 
Ackr4−/− early PB and early GC B cell responses (day 5 after 
SRBC administration) in the context of mixed BM chimeras. 
In mice reconstituted with an equal mixture of Ackr4−/− and 
WT BM, ACKR4 deficiency enhanced early PB and early 
GC B cell responses relative to concurrently activated WT 
cells (Fig. 3 A). To extend these observations, we studied con-
current WT (CD45.1/2) and Ackr4−/− (CD45.2) SWHEL B 
cell responses to the reduced affinity HEL mutant HEL2X (Ka 
= 8 × 107 M−1). This response forms early PBs, GC B cells, 
and a population of cells (B220+Ig[HEL]hiGL7-) that likely 
encompass early memory B cells (Chan et al., 2009; Brink 
et al., 2015) by day 5 after immunization. At this time point, 
Ackr4−/− SWHEL B cells outcompeted WT SWHEL B cells in 
the early PB and GC B and B220+HELhiGL7− cell popula-
tions, most prominently among SWHEL early PBs (Fig. 3 B). 
We hypothesized further that enforced expression of ACKR4 
prior to B cell activation by antigens may limit entry into 
early PB and GC B cell compartments. We tested this by 
generating Ackr4 knockin mice (Rosa26LSL-Ackr4; Fig. S2 A) 
and making expression conditional to follicular (Fo) B cells 
by introducing a Cre recombinase driven by the regulatory 
elements of Cd23 (Cd23Cre; Kwon et al., 2008). Fo B cells 
from Cd23Cre/+.Rosa26LSL-Ackr4/+ mice expressed functional 
ACKR4 (Fig. S2, B and C) and had frequencies of splenic Fo 
B cells and marginal-zone B cells that were equivalent to WT 
littermates (Fig. S2 D). Transgenic ACKR4 expression by Fo 
B cells did not alter CCR7 or CXCR5 expression at rest or 
after anti–IgM stimulation (Fig. S2 E), but, consistent with the 
known function of ACKR4 as a scavenger of CCR7 ligands 
(Comerford et al., 2006, 2010), inhibited anti-IgM–stimu-
lated B cell migration toward CCL21, but not CXCL13, a 
non-ACKR4 ligand in mice (Townson and Nibbs, 2002; Fig. 
S2 F). Supporting the hypothesis that ACKR4 negatively reg-
ulates activated B cell differentiation, in mixed BM chimeric 
mice reconstituted with Cd23Cre/+.Rosa26LSL-Ackr4/+ and WT 
BM, ACKR4 transgenic B cells were less represented among 
early PB and GC B cells that form on day 5 of the SRBC 
response (Fig. 3 C). These data suggest that enforced ACKR4 
expression in Fo B cells limits their ability to form early PB 
and GC B cells when in competition with WT cells. Col-
lectively, we conclude that ACKR4 negatively regulates early 
PB and GC B cell responses in a B cell–intrinsic manner. 
Furthermore, these experiments did not reveal a cell-intrinsic 
role for ACKR4 in TFH or TFR development (Fig. S1 C), 
suggesting that the enhanced T cell responses observed in 
H-Ackr4−/− and B-Ackr4−/− mice (Fig. S1, A and B) are sec-
ondary to enhanced B cell responses, an observation that is in 
keeping with recent evidence, indicating that the magnitude 
of the TFH cell response is proportional to the magnitude of 
the GC B cell response (Baumjohann et al., 2013).
To examine ACKR4-dependent regulation of the ini-
tial antigen-engaged B cell differentiation in more detail, we 
tracked early WT and Ackr4−/− SWHEL B cell responses to 
HEL2X using mixed SWHEL B cell transfers. Profiling CFSE 
dilution revealed a cell-intrinsic proliferative advantage for 
Ackr4−/− over WT SWHEL B cells as early as day 2 (Fig. 4 A), 
which was increasingly apparent as the response progressed 
(Fig.  4  B). Notably, the magnitude of the advantage for 
Ackr4−/− SWHEL B cells on day 3 of the reaction (KO:WT = 
1.26 ± 0.01) was similar to their advantage among the day 5 
GC B cell (KO:WT = 1.36 ± 0.01; Fig. 3 B) and B220+HEL-
hiGL7− cell (KO:WT = 1.49 ± 0.02; Fig. 3 B) populations. 
These findings suggest that enhanced early proliferation of 
responding Ackr4−/− SWHEL B cells may contribute to their 
accumulation among the effector cell compartments by day 
5 of the reaction (Fig. 3 B). In experiments in which WT or 
Ackr4−/− SWHEL B cells were transferred into separate recip-
ients, Ackr4−/− SWHEL B cells were detected at greater fre-
quencies by day 2.5, and remained more abundant during 
the first 5.5 d of the response (Fig. 4 C). By day 5.5, mice re-
ceiving Ackr4−/− SWHEL B cells had an increased total num-
ber of early PBs, GC B cells, and B220+HELhiGL7− cells per 
spleen compared with controls (Fig. 4 D). Ackr4−/− SWHEL 
B cells showed a greater propensity to form early PBs (Fig. 4, 
E and F), which was apparent by flow cytometry on day 4.5 
(Fig. 4 G) and translated to increased circulating anti–HEL 
IgM and IgG1 titers and kinetics (Fig. 4 H). Together, these 
findings suggest that ACKR4 limits early antigen-engaged B 
cell proliferation in a B cell–intrinsic manner, reducing the 
number of antigen-engaged B cell precursors available for 
early PB and GC B cell differentiation.
Comparisons of SWHEL B cell responses elicited by HEL 
antigens that differ in their affinity for HyHEL10 (Paus et al., 
2006; Chan et al., 2009), or conjugated to SRBCs at varying 
epitope densities (Paus et al., 2006), have revealed that affinity 
and/or avidity of initial BCR-mediated activation positively 
regulates the initial expansion of antigen-engaged B cells. To 
investigate whether ACKR4-dependent changes to activated 
B cell responses were congruent across different initiating af-
finities and/or avidities of BCR-mediated activation, we stud-
ied WT (CD45.1/2) and Ackr4−/− (CD45.2) SWHEL B cell 
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Figure 2. ACKR4 in GC biology. (A) Representative histology of CCL21 (green) abundance surrounding mesenteric LN GCs in H-WT and H-Ackr4−/− mice. 
BCL-6, blue; IgD, white; and CD3, red. Right: IgD and CCL21 staining. Middle: IgD, BCL6, and CCL21 staining. Left: All stains merged. Bars, 50 µm. n = 2–3 
mice/genotype. (B) Representative DZ (CXCR4hiCD86lo) and LZ (CXCR4loCD86hi) phenotype staining and ratios among splenic GC B cells (B220+IgD−Fas+GL7+) 
from H-WT and H-Ackr4−/− mice day 8 after SRBC. n = 8 mice/genotype (means ± SEM). (C) BrdU (2 mg) was administered i.p. 5 h before euthanasia. Repre-
sentative BrdU and 7-aminoactinomycin D (DNA content) staining and quantitation of splenic GC B cells from H-WT and H-Ackr4−/− mice day 8 after SRBC. 
n = 5 mice/genotype (means ± SEM). (D) Representative staining and quantitation of Annexin V+ splenic GC B cells day 8 after SRBC. n = 5 mice/genotype. 
(E) Total mutation (left; means ± SD) and high-affinity W33L mutation (right) frequency per VH186.2 gene segment from single WT and Ackr4−/− NP+IgG1+ 
splenic GC B cells day 14 after NP-KLH immunization. Numbers in doughnut plots indicate the number of W33L+ sequences of the total VH186.2+ sequences 
analyzed. (F) Total (NP32) and the NP5/NP32 titer of serum NP-specific IgG antibodies in H-WT and H-Ackr4−/− mice day 21 after NP-KLH immunization. n = 
8 mice/genotype (means ± SEM). (G) Experimental schematic. WT (CD45.1/2) and Ackr4−/− (CD45.2) SWHEL B cells were cotransferred into B6.Ly5.1 (CD45.1) 
mice and immunized the next day with HEL3X-SRBC. (H and I) Representative flow cytometric DZ/LZ ratio (H) and HEL4X (I; high-affinity) staining on concur-
rent WT and Ackr4−/− SWHEL GC B cells (B220+HEL+CD138−GL7+) on day 9. n = 5 mice. Numbers in plots present means ± SEM (A–I). Data are representative 
of one (A and E) and two (B–D and F–I) independent experiments. ****, P < 0.0001. (B–D and F) Two-tailed, unpaired Student’s t test. (E) Two-tailed, unpaired 
Student’s t test (left), Fisher’s exact test (right, doughnut plots). (H and I) Two-tailed, unpaired Student’s t test.
ACKR4 shapes activated B cell fate | Kara et al.806
responses to intermediate (HEL2X)- or low (HEL3X)-affinity 
HEL proteins conjugated to SRBCs at intermediate or low 
epitope densities (Fig.  4  I; Paus et al., 2006; Chan et al., 
2009). Ackr4−/− SWHEL B cells preferentially formed early 
PBs (Fig. 4 J) and outcompeted WT cells in GC B cell and 
B220+HELhiGL7- cell compartments 5 d after immuniza-
tion when either HEL2X or HEL3X of equivalent intermedi-
ate epitope densities were used (Fig. 4 K). Conversely, when 
the epitope density was reduced (low density), both WT and 
Ackr4−/− SWHEL PB responses were barely detectable by flow 
cytometry on day 5 (Fig. 4 J), but the cell-intrinsic advantage 
for Ackr4−/− SWHEL GC B cell and B220+HELhiGL7- cell 
development at that time point remained apparent (Fig. 4 K). 
These data indicate that ACKR4-dependent negative regula-
tion of B cell responses is independent of the initiating affin-
ity or avidity of BCR-mediated activation.
To explore the relationship between ACKR4 func-
tion as a regulator of CCR7-dependent cellular migration 
and its negative regulation of activated B cell responses, we 
studied the distribution of WT and Ackr4−/− SWHEL B cells 
within the spleen after HEL2X-SRBC immunization using 
histology (Fig. 5 A). WT and Ackr4−/− SWHEL B cells were 
located throughout B cell follicles before immunization 
(unpublished data). Within 24 h, a proportion of WT SWHEL 
B cells had redistributed along the T/B border or had em-
igrated into the T cell zone. By days 2–2.5, most of the 
Figure 3. ACKR4 limits early B cell re-
sponses in a B cell–intrinsic manner. (A) 
Mixed BM chimeras were generated with an 
equal mixture of B6.Ly5.1 (CD45.1) and WT 
or Ackr4−/− (both CD45.2) BM. Representative 
plots of CD45.2+ cells among Fo B cells (B220+Ig-
D+Fas−GL7−), GC B cells (B220+IgD−Fas+GL7+), 
and early PBs (B220lo/-CD138+) 5 d after SRBC. 
Gating of these populations is shown. Compet-
itive ratios of GC B cells (left graph) and early 
PBs (right graph) are plotted as the frequen-
cies of CD45.2+ cells in each compartment, 
normalized to the frequencies of CD45.2+ 
cells in the concurrent Fo B cell compartment. 
n = 6 mice/genotype (means ± SEM). (B) WT 
(CD45.1/2) and Ackr4−/− (CD45.2) SWHEL B cells 
were cotransferred into B6.Ly5.1 (CD45.1) 
mice and immunized with HEL2X-SRBC (n = 
4 mice) or mock-conjugated SRBCs (n = 3 
mice). Contribution of WT and Ackr4−/− cells to 
SWHEL GC B cell (B220+Igκ+HELintGL7+CD138−), 
early PBs (B220lo/-Igκ+HEL+CD138+), and 
B220+HELhiGL7− (also Igκ+CD138−) cell pop-
ulations 5 d after immunization. The SWHEL.
Ackr4−/− competitive ratio is plotted as the 
ratio of Ackr4−/− to WT among SWHEL effector 
cell compartments from day 5 HEL2X-SRBC–
immunized mice, normalized to the input ratio 
(as determined from mock-SRBC immunized 
mice analyzed on day 5 [means ± SEM]). (C) 
Cd23Cre/+.Rosa26LSL-Ackr4/+ mixed BM chimeras 
were generated and analyzed as in A (n = 6–7 
mice/genotype; mean ± SEM). (A–C) Data are 
representative of two (B and C) and three (A) 
independent experiments. Two-tailed, unpaired 
Student’s t test. ***, P < 0.001; ****, P < 0.0001.
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Figure 4. ACKR4 limits early proliferation of antigen-engaged B cells and limits early PB responses. (A and B) WT (CD45.1/2) and Ackr4−/− (CD45.2) 
SWHEL B cells were cotransferred into B6.Ly5.1 (CD45.1) mice and immunized with HEL2X-SRBC. (A) Representative flow-cytometric CFSE profiles and analysis 
of CFSE GMFI among responding SWHEL B cells (B220+Igκ+HEL+CD138−) on day 2 (n = 6). Undivided SWHEL B cells were analyzed from mock-SRBC–immu-
nized recipients (n = 2). (B) Contribution of WT and Ackr4−/− among responding SWHEL B cells (B220+Igκ+HEL+CD138−) over the first 3 d of the HEL2X-SRBC 
response (n = 4 mice/time point). (C–H) WT or Ackr4−/− (both CD45.2) SWHEL B cells were transferred into B6.Ly5.1 (CD45.1) mice and immunized with 
HEL2X-SRBC (n = 4 mice/genotype per time point). (C) Frequency of total responding SWHEL B cells (CD45.2+Igκ+HEL+) per 106 splenocytes (means ± SEM). 
(D) Representative plots of early PB and GC B cell and B220+HELhiGL7− cell responses as a frequency of total responding SWHEL B cells (plots are pregated 
CD45.2+Igκ+HEL+) on day 5.5. Numbers in plots represent the means ± SEM frequency of early PBs, GC B, or B220+HELhiGL7− cells as the frequency of the 
total responding SWHEL B cells. (E) Frequency of SWHEL B220+HELhiGL7− cells, GC B cells and early PBs (gated as shown in D) per 106 splenocytes and total 
number per spleen on day 5.5 (means ± SEM). (F) Representative histology of responding SWHEL B cells on day 5.5 (n = 4 mice/genotype). Bar, 200 µm. HEL, 
green; IgD, blue; and CD4, red. (G) Frequency of SWHEL early PBs (gated as in E) per 106 splenocytes (means ± SEM). (H) Anti-HEL IgM and IgG1 serum con-
centration as determined by ELI SA (see Materials and methods; means ± SEM). (I–K) WT (CD45.1/2) and Ackr4−/− (CD45.2) were cotransferred into B6.Ly5.1 
(CD45.1) recipients and immunized with HEL2X (intermediate affinity) or HEL3X (low affinity) conjugated to SRBCs at intermediate or low epitope densities (n 
= 4 mice/genotype per condition). (I) HEL2X or HEL3X were conjugated to SRBCs at intermediate (black histogram; 100 µg/ml; SRBC) and low (gray histogram; 
5 µg/ml; SRBC) epitope densities and detected using HyHEL9 mAb. Mock-conjugated SRBCs (open histogram) are shown for comparison. (J) Representative 
plots of concurrent WT and Ackr4−/− SWHEL early PBs on day 5 (pregated Igκ+HEL+ and CD45.1+CD45.2+ [WT] or CD45.1−CD45.2+ [Ackr4−/−]). Numbers in 
plots represent the mean (± SEM) frequency of early PB as the frequency of total responding SWHEL B cells. (K) SWHEL.Ackr4−/− competitive ratio is plotted 
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WT SWHEL B cells remained at the T/B border, although 
some redistribution to the interfollicular zone (IFZ; defined 
here as the lateral poles of the Fo B cell proximal to bridg-
ing regions, also referred to as the marginal-zone bridging 
channel) was apparent. In contrast, an increased proportion 
of Ackr4−/− SWHEL B cells were localized in the IFZ early 
during the response. On days 2–2.5, a larger proportion of 
Ackr4−/− SWHEL B cells were localized in the IFZ and were 
visibly more abundant than the WT SWHEL B cell response 
at that time, which became increasingly apparent during the 
next 60 h of the response. Whereas most WT SWHEL B cells 
were positioned in the IFZ and at the T/B border on days 
3–3.5, a proportion of Ackr4−/− SWHEL B cells were distrib-
uted in the outer follicle, with the emergence of SWHEL B 
cell clusters in the outer follicular regions and the IFZ and 
the appearance of cells exhibiting a PB phenotype in the 
bridging channels on day 3, which became more obvious 
by days 3.5–4.5. These early ACKR4-dependent changes 
to the migratory patterns of SWHEL B cells were indepen-
dent of detectable cell-intrinsic defects in CCR7, CXCR5, 
CXCR4, or EBI2 expression during the first 3 d of this re-
sponse (Fig. 5 B). Thus, in the absence of ACKR4, a propor-
tion of activated B cells preferentially home to the splenic 
IFZ during the early stages of the humoral immune response. 
Favorable positioning to interfollicular niches was accompa-
nied with the enhanced expansion of Ackr4−/− SWHEL B 
cells in these zones and exaggerated early PB responses.
CCR7 guides activated B cell homing toward the T/B 
border but also contributes to the lateral spreading along 
that interface and positioning within the splenic IFZ (Reif 
et al., 2002; Okada et al., 2005; Gatto et al., 2011). To deter-
mine whether ACKR4-mediated regulation of early B cell 
responses was dependent on CCL19 and/or CCL21, these 
ligands were neutralized in mixed BM chimeras. This revealed 
that the advantage of ACKR4-deficient B cells to enter early 
PB and GC B cell compartments was dependent, at least in 
part, on physiological CCL19/CCL21 (Fig. 5 C).
Concluding remarks
Our findings establish ACKR4 as a B cell–intrinsic reg-
ulator of early PB and GC B cell responses. First, using 
ACKR4-deficient anti-HEL monoclonal B cells, we 
demonstrate that ACKR4 limits the early migration of an-
tigen-engaged B cells to splenic interfollicular niches. Un-
restricted access of activated B cells to these niches in the 
absence of ACKR4 was associated with their enhanced early 
expansion, which we propose increased the precursor pool 
of activated B cells available for subsequent differentiation 
into early PB and GC B cell fates. Further, we demonstrate 
that aberrant, splenic IFZ localization by antigen-engaged 
ACKR4-deficient anti-HEL B cells was accompanied by the 
preferential formation of early PB responses.
Existing evidence indicates that migration of activated 
B cells is predominantly shaped by their balanced responsive-
ness to CCR7, EBI2, CXCR5, and CXCR4 ligands (Pereira 
et al., 2010). Gatto et al. (2011) demonstrated that transfer 
of Cxcr5-deficient, activated B cells results in their exclu-
sion from B cell follicles and accumulation in marginal-zone 
bridging channels; however, compound deletion of Cxcr5 
with Ccr7 was shown to direct cells away from this niche and 
toward the outer regions of the follicle. These data indicate 
that, in addition to its established role as driving activated 
B cell migration toward the T cell zone (Reif et al., 2002), 
CCR7 also contributes to positioning activated B cells to-
ward the IFZ and bridging zones of the spleen. Our experi-
ments with SWHEL B cells indicate that deletion of ACKR4, a 
scavenger of CCR7 ligands, promotes responding B cell mi-
gration to splenic IFZ. We speculate that ACKR4 may func-
tion to “tune” early CCR7-dependent cues on a proportion 
of responding B cells, limiting their CCR7-driven homing 
to splenic IFZ. Our findings that physiological CCL19 and 
CCL21 were required, at least in part, for ACKR4-dependent 
changes to early PB and GC B cell responses supports a rela-
tionship between ACKR4 and CCR7 function in the regula-
tion of activated B cell responses.
Our results indicate that the propensity of ACKR4- 
deficient SWHEL B cells to form early PB responses correlated 
with their favorable accumulation in the IFZ during the early 
stages of T cell–dependent humoral immunity. These data, 
together with published findings that (a) EBI2-deficient B 
cells, which are defective in their ability to access splenic IFZ 
and bridging channels, fail to form robust early PB responses 
(Gatto et al., 2009); (b) forced EBI2 expression on B cells pro-
motes early PB responses (Gatto et al., 2009); and (c) targeted 
antigen delivery to splenic DCIR2+ dendritic cells, which 
localize to this niche, elicit robust early PB responses, and are 
implicated in promoting PB survival (García De Vinuesa et 
al., 1999; Chappell et al., 2012), support a model in which B 
cell migration at the early stages of activation has an import-
ant role in coordinating and balancing differentiation to early 
PB and GC B cell fates.
In summary, our results describe an in vivo, cell-intrinsic 
role for ACKR4 in shaping activated B cell differentiation 
and further our understanding of the cellular events that gov-
ern antibody production.
MATERIALS AND METHODS
Mice
All mice were on the C57BL/6J background and housed 
in specific pathogen-free conditions at Laboratory Animal 
as the ratio of Ackr4−/− to WT among SWHEL GC B cell (left) or B220+HELhiGL7− cell (right) compartments (gated as in D), normalized to the input ratio, as 
determined from mock-SRBC–immunized mice. n = 4 mice (means ± SEM) on day 5. (A–K) *, P < 0.05; **, P < 0.01; ****, P < 0.0001; data are representative 
of two independent experiments. (A and J) Two-tailed, paired Student’s t test. (B and C–H) Two-tailed, unpaired Student’s t test. (C–K) Means ± SEM.
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Services, University of Adelaide (unless indicated oth-
erwise). C57BL/6 (WT) and B6.Ly5.1 (B6.SJL Ptprca) 
were purchased from the Animal Resource Center and 
bred in house. Ackr4−/−, Ccr7−/−, μMT, Ackr4−/−.Ccr7−/− 
SWHEL (CD45.2), SWHEL (CD45.1/2), and SWHEL.
Ackr4−/− (CD45.2) mice were bred and maintained in 
house. Cd23Cre mice were provided by M. Busslinger (Re-
search Institute of Molecular Pathology, Vienna, Austria). 
Cd23Cre.Rosa26LSL-Ackr4/+ mice were generated by inter-
breeding and maintained in house. Mice used in exper-
iments were gender- and age-matched animals and were 
between the ages of 6 and 12 wk. All animal experiments 
were approved by the Animal Ethics Committee of the 
University of Adelaide.
Figure 5. ACKR4 limits early localization 
of antigen-engaged B cells to splenic IFZs. 
(A) WT or Ackr4−/− SWHEL B cells were trans-
ferred into WT recipients and immunized the 
next day with HEL2X-SRBC (days 1–2.5 analysis, 
transfer of 5 × 105 SWHEL B cells, immunization, 
2 × 109 HEL2X-SRBC; and days 3–4.5 analysis, 
transfer of 2 × 105 SWHEL B cells, immunization, 
109 HEL2X-SRBC). Representative histology 
of responding SWHEL B cells in the spleen on 
days 1, 2, 2.5, 3, 3.5, and 4.5 after immuniza-
tion. Quantification of SWHEL B cell frequency 
per splenic region is depicted for days 1, 2, 
and 2.5 (see Materials and methods; means ± 
SEM). Bar, 200 µm. Blue, IgD; green, HEL; red, 
CD4; OF, outer follicle; FC, follicle center; T/B, 
T/B border; TCZ, T cell zone. Images are repre-
sentative of five mice/genotype per time point; 
two-tailed, unpaired Student’s t test. (B) WT 
(CD45.1/2) and Ackr4−/− (CD45.2) SWHEL B cells 
were cotransferred into B6.Ly5.1 (CD45.1) 
mice and immunized with HEL2X-SRBC. Rep-
resentative plots of CCR7, CXCR5, CXCR4, 
and EBI2 staining on responding SWHEL B cells 
(B220+Igκ+HEL+) relative to endogenous Fo B 
cells (CD45.1+CD45.2−B220+IgDhi). Numbers 
indicate the fold change (means ± SEM) in sur-
face receptor GMFI on WT and Ackr4−/− SWHEL 
B cells relative to the concurrent endogenous 
Fo B cells (n = 5 mice/time point). (C) Mixed 
BM chimeras were generated with 80% BM 
from B6.Ly5.1 (CD45.1) and 20% from WT or 
Ackr4−/− (both CD45.2). Mice were adminis-
tered polyclonal rabbit sera containing 500 µg 
anti–CCL19 and 500 µg anti–CCL21 or 1 mg 
normal rabbit IgG i.p. on days −1, 0, 2, and 
4. Mice were immunized with SRBC on day 0 
and analyzed on day 5. Competitive ratios of 
early PB (left; B220lo/-CD138+) and GC (right; 
B220+IgD−Fas+GL7+) B cells are plotted as the 
frequencies of CD45.2+ cells in each compart-
ment normalized to the frequency of CD45.2+ 
cells in the concurrent Fo B cell (B220+IgD+-
Fas−GL7−) compartment (n = 4–7 mice/gen-
otype; means ± SEM). Two-tailed unpaired 
Student’s t test. (A–C) Data are representative 
of two independent experiments. *, P < 0.05; 
**, P < 0.01; ****, P < 0.0001.
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BM chimeras
Recipient mice were lethally irradiated with 1,000 rad (two 
doses of 500 rad) and reconstituted with 4–5 × 106 total BM 
cells i.v. of genotypes indicated in text. A minimum of 8 wk 
was allowed for reconstitution before experimentation.
Transfers, immunizations, and BrdU treatment
T cell–dependent humoral immune responses were induced 
with 2 × 109 SRBC (Applied Biological Products) or 50 µg 
NP-KLH (Biosearch Technologies) and precipitated in alum 
(Analar) i.p. HEL2X, HEL3X, and HEL4X, with varying affini-
ties to HyHEL10, as described (Brink et al., 2015). Conjuga-
tion of HEL proteins to SRBCs was performed as described 
(Brink et al., 2015). Unless otherwise indicated, HEL con-
jugation to SRBCs was performed using 300 µg/ml HEL. 
Successful conjugation was confirmed using HyHEL9 mAb 
(Brink et al., 2015) before immunization. Unless otherwise 
indicated, splenocytes or Fo B cells purified by magnetic- 
activated cell sorting (CD43 Negative Isolation kit; Miltenyi 
Biotech) from SWHEL or SWHEL.Ackr4−/− mice containing 
105 HEL-binding B cells were transferred i.v. into B6.Ly5.1- 
recipient mice. The next day, recipient mice were immu-
nized i.v. with 109 HEL-conjugated SRBCs. For assessment 
of SWHEL B cell proliferation, splenocytes containing SWHEL 
B cells were CFSE loaded, as described (Quah et al., 2007), 
before transfer and immunization the next day. For BrdU ex-
periments, 2 mg BrdU (Sigma-Aldrich) in 0.85% saline was 
injected i.p. 5 h before euthanasia.
Histology
For assessment of SWHEL B cell responses by histology (days 
1–2.5), 5 × 105 HEL-binding B cells from SWHEL or SWHEL.
Ackr4−/− mice were transferred i.v. into WT mice, which 
were immunized with 2 × 109 HEL2X-SRBC i.v. the next 
day. For assessment of SWHEL B cell responses by histology 
(days 3–5.5), 2 × 105 HEL-binding B cells from SWHEL or 
SWHEL.Ackr4−/− mice were transferred i.v. into WT mice, 
which were immunized with 109 HEL2X-SRBC i.v. the next 
day. Organs were frozen in Tissue-Tek optimal cutting tem-
perature–embedding medium (Sakura Finetek). Cryostat sec-
tions (8 µm) were fixed in ice-cold acetone and stained, as 
previously described (Bunting et al., 2013). For detection of 
HEL-binding B cells, sections were first blocked with 30% 
normal horse serum and incubated with HELWT (100 ng/
ml; Sigma-Aldrich), which was detected using unconjugated 
rabbit anti–HEL (polyclonal; Rockland) and goat anti–rabbit 
Ig-Alexa Fluor 488 (Life Technologies). For SWHEL histology, 
antibodies to IgD (11-26c; eBioscience) and CD4 (RM4-5; 
BD) were used. For the GC stain (Fig. 2 A), antibodies to IgD, 
CD3 (145-2C11; BD), BCL-6 (K112-91; BD), and CCL21 
(goat polyclonal; R&D) were used. To enumerate transferred 
SWHEL B cell positioning in spleen sections, the outer follicle, 
follicle center, T/B interface, IFZs, and T cell zone per white 
pulp region were first defined (Gatto et al., 2011) in a blinded 
manner on images stained with IgD/CD4, with HEL-bind-
ing fluorescence removed. HEL-binding fluorescence was 
then merged with these images, and the total number of 
HEL-binding cells per white pulp area and HEL-binding 
cells in defined regions were enumerated by four indepen-
dent researchers. Means ± SEM values across those four inde-
pendent data sets are presented.
In vivo CCL19/CCL21 neutralization
Affinity-purified anti–mouse (m) CCL21 was generated 
and purified in house as described (Comerford et al., 2010). 
Anti–mCCL19 antibodies were raised in New Zealand 
white rabbits by immunization with full-length, synthetically 
manufactured CCL19, which was active in calcium mobi-
lization and chemotaxis assays (Clark-Lewis et al., 1994). 
Serum IgG was purified from preimmunized bleeds (nor-
mal rabbit IgG [NRIgG]) and mCCL19- or mCCL21-im-
munized rabbits using Protein A columns (Millipore). The 
CCL19- or CCL21-neutralizing ability of these antibodies 
was confirmed in chemotaxis assays before their use in vivo. 
Recipient, mixed-BM chimeric mice were administered 500 
µg affinity-purified rabbit anti–mCCL21 and 500 µg affin-
ity-purified, rabbit anti–mCCL19 or 1 mg NRIgG i.p. on 
days −1, 0, 2, and 4. Mice were immunized with SRBCs i.p. 
on day 0 and analyzed 5 d later.
VH gene sequencing analysis of NP+IgG1+ GC B cells
Single NP+IgG1+ GC B cells were sorted from NP-KLH–
immunized (day 14) mice using a BD FAC SAria cell sorter. 
Two rounds of PCR were performed on cDNA using a sin-
gle proximal 5′ primer for the J558 VH gene family (Ehlich 
et al., 1994; Smith et al., 2000), together with nested primers 
specific for Cγ1 (McHeyzer-Williams et al., 1991; Smith et 
al., 2000). Bands of expected size were purified, sequenced, 
and analyzed for VH186.2-containing sequences as described. 
For VH186.2+ clones, the region encoding amino acids 10–96 
were compared in detail with the germline VH186.2 sequence 
as described (Smith et al., 2000).
Chemotaxis assay
Fo B cells purified by magnetic-activated cell sorting were 
activated with 5 µg/ml goat anti–mouse IgM (Jackson Im-
munoResearch) for 24 h or rested overnight (unstimulated 
control). Various dilutions of recombinant mouse CCL21 
(provided by the late I. Clark-Lewis) or CXCL13 (Pepro-
Tech) in 150 µl chemotaxis buffer (RPMI-1640 with 0.5% 
BSA and 20  mM Hepes) were added to the lower cham-
bers of Transwell chemotaxis plates (96-well, 5-µm pore size; 
Corning). Cells were extensively washed in chemotaxis buf-
fer and loaded into the upper chambers at 105 cells/well in 
50 µl chemotaxis buffer and incubated for 3 h at 37°C. To 
enumerate B cell migration, cells were harvested from the 
bottom chambers, and B220+ cells were assessed by flow cy-
tometry using a defined number of CaliBRI TE beads (BD) 
as an internal reference. The migration index was calculated 
as described (Kara et al., 2013).
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Chemokine-scavenging assay
FACS-sorted Fo B cells (2 × 105) were incubated in RPMI-
1640 medium containing 5 or 10 ng/ml recombinant mouse 
CCL19 (R&D Systems) at 37°C for 3 h with inversion every 
30 min. 100 µl of cell-free supernatant was then assessed for 
CCL19 concentration by ELI SA as described previously 
(Comerford et al., 2010).
ELI SA
Serum HEL-specific IgM and IgG1 concentrations were 
quantified using HyHEL10 IgM and IgG1 standards as de-
scribed previously (Phan et al., 2003). NP-specific IgG was 
detected using NP5-BSA or NP32-BSA (10 µg/ml; Biosearch 
Technologies)–coating antigen. ELI SAs were developed with 
3,3′,5,5′-tetramethylbenzidine substrate.
Quantitative PCR
RNA was harvested using the Qiagen microRNeasy kit with 
on-column DNase treatment. cDNA synthesis was performed 
using Transcriptor First Strand cDNA synthesis kit (Roche) 
and used as the template in reactions with the LightCycler 
480 SYBR Green Master Mix I (Roche). Relative Ackr4 
transcript abundance was calculated with reference to the 
housekeeping gene Rplp0 using the formula: 2−ΔCT (ΔCT 
= CTAckr4 – CTRplp0); Rplp0, forward: 5′-AGA TGC AGC 
AGA TCC GCAT-3′, reverse: 5′-CAG TGA GCT TCC CGT 
TCAG-3′; Ackr4, forward: 5′-AGA TGC AGC AGA TCC 
GCAT-3′, reverse: 5′-CAG TGA GCT TCC CGT TCAG-3′.
Flow cytometry and sorting
Cells were stained as described previously (Kara et al., 2015) 
using antibodies specific for: CD45.2 (104), B220 (RA3-6B2), 
IgD (11-26c), IgDb (217–170), Fas (Jo2), GL7, CD86 (GL1), 
CD138 (281–2), Igκ (RMK-45), CD93 (AA4.1), CD21 
(7G6), CD23 (B3B4), CD11b (M1/70), CD3 (145-2C11), 
CD4 (RM4-5), CD44 (IM7), PD-1 (J43), CXCR5 (2G8), and 
CCR7 (4B12; in house); and EBI2 (chicken polyclonal; Gatto 
et al., 2013), CXCR4 (2B11/CXCR4), Nrp-1 (3E12), and 
Foxp3 (FJK-16s). Unconjugated/biotinylated antibodies were 
detected using goat anti–rat IgG (Life Technologies), goat anti–
human IgG-Fcγ fragment specific (Jackson ImmunoResearch), 
streptavidin-PE (Jackson ImmunoResearch), -Alexa Fluor 647 
(Jackson ImmunoResearch), -BV510, -BV421, or -BV450. All 
antibodies and secondary reagents were purchased from BD, 
eBioscience, or BioLegend unless otherwise indicated. Dead 
cells were excluded using LIVE/DEAD fixable near-infrared 
dye (Molecular Probes). 7-aminoactinomycin D (eBioscience) 
was used to detect DNA content. BrdU staining was conducted 
using the BrdU Flow kit (BD). NP-binding was detected using 
NP-PE made in house (Smith et al., 2000). CCL19-Fc is a chi-
meric protein of mouse CCL19 fused to human IgG1 constant 
region (Reif et al., 2002). The Annexin V apoptosis detection 
kit (eBioscience) was used to detect Annexin V. Foxp3/TF 
staining buffer set (eBioscience) was used to detect FoxP3. For 
detection of HEL-binding cells, 2 × 106 splenocytes were incu-
bated with soluble HEL (200 ng/ml), followed by detection of 
BCR-bound HEL using mAb HyHEL9 conjugated to Alexa 
Fluor 647 as described (Brink et al., 2015). Data were acquired 
on BD LSR II, BD FAC SAria, or BD LSRFortessa flow cy-
tometers. For sorting experiments, a BD FAC SAria was used. 
Data were analyzed using FlowJo software (Tree Star).
Statistics
Data were analyzed with Prism (GraphPad Software) using 
either two-tailed (unpaired or paired, as appropriate) Student’s 
t tests (for normally distributed data sets comparing the mean 
of two samples), two-tailed nonparametric Mann-Whitney 
tests (for data sets that were determined by an F test not to 
have a normal distribution and where there was a comparison 
of the mean of two samples), or one-way analysis of vari-
ance with appropriate posttests as indicated in text (for com-
parisons of multiple samples). For all analyses, P < 0.05 was 
considered significant. Sample or experiment sizes were de-
termined empirically for sufficient statistical power. No statis-
tical tests were used to predetermine the size of experiments. 
No data points were excluded from statistical tests.
Online supplemental material
Fig. S1 shows that follicular T cell responses to SRBC immu-
nization are enhanced in the absence of hematopoietic or B 
cell expression of ACKR4. Fig. S2 shows the generation and 
characterization of Rosa26LSL-Ackr4 knockin mice.
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